A randomized, controlled, repeat-dose study of batefenterol/fluticasone furoate compared with placebo in the treatment of COPD

BACKGROUND: Batefenterol (BAT) is a bi-functional molecule with both muscarinic antagonist and β(2)-adrenoceptor agonist pharmacology. This Phase II, randomized, placebo-controlled, double-blind study evaluated the safety and tolerability of BAT 300 μg with fluticasone furoate (FF) 100 μg administer...

Descripción completa

Detalles Bibliográficos
Autores principales: Crim, Courtney, Gotfried, Mark, Spangenthal, Selwyn, Watkins, Michael, Emmett, Amanda, Crawford, Catriona, Baidoo, Charlotte, Castro-Santamaria, Ramiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7199364/
https://www.ncbi.nlm.nih.gov/pubmed/32366249
http://dx.doi.org/10.1186/s12890-020-1153-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7199364/
https://www.ncbi.nlm.nih.gov/pubmed/32366249
http://dx.doi.org/10.1186/s12890-020-1153-7

Ejemplares similares